These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Inclisiran-New hope in the management of lipid disorders? Dyrbuś K; Gąsior M; Penson P; Ray KK; Banach M J Clin Lipidol; 2020; 14(1):16-27. PubMed ID: 31879073 [TBL] [Abstract][Full Text] [Related]
7. PCSK9 targets important for lipid metabolism. Schulz R; Schlüter KD Clin Res Cardiol Suppl; 2017 Mar; 12(Suppl 1):2-11. PubMed ID: 28176216 [TBL] [Abstract][Full Text] [Related]
8. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons. Yadav K; Sharma M; Ferdinand KC Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986 [TBL] [Abstract][Full Text] [Related]
9. PCSK9 inhibition for LDL lowering and beyond - implications for patients with peripheral artery disease. Gebauer K; Reinecke H Vasa; 2018 Apr; 47(3):165-176. PubMed ID: 29412075 [TBL] [Abstract][Full Text] [Related]
10. Harnessing RNA Interference for Cholesterol Lowering: The Bench-to-Bedside Story of Inclisiran. Wilkinson MJ; Bajaj A; Brousseau ME; Taub PR J Am Heart Assoc; 2024 Mar; 13(6):e032031. PubMed ID: 38456415 [TBL] [Abstract][Full Text] [Related]
11. Inclisiran for the treatment of dyslipidemia. Nishikido T; Ray KK Expert Opin Investig Drugs; 2018 Mar; 27(3):287-294. PubMed ID: 29451410 [TBL] [Abstract][Full Text] [Related]
13. Changes in circulating pro-protein convertase subtilisin/kexin type 9 levels - experimental and clinical approaches with lipid-lowering agents. Macchi C; Banach M; Corsini A; Sirtori CR; Ferri N; Ruscica M Eur J Prev Cardiol; 2019 Jun; 26(9):930-949. PubMed ID: 30776916 [TBL] [Abstract][Full Text] [Related]
14. Low-density Lipoprotein-Cholesterol Lowering Strategies for Prevention of Atherosclerotic Cardiovascular Disease: Focus on siRNA Treatment Targeting PCSK9 (Inclisiran). Sinning D; Landmesser U Curr Cardiol Rep; 2020 Oct; 22(12):176. PubMed ID: 33089390 [TBL] [Abstract][Full Text] [Related]
15. How much should LDL cholesterol be lowered in secondary prevention? Clinical efficacy and safety in the era of PCSK9 inhibitors. Cybulska B; Kłosiewicz-Latoszek L; Penson PE; Nabavi SM; Lavie CJ; Banach M; Prog Cardiovasc Dis; 2021; 67():65-74. PubMed ID: 33383060 [TBL] [Abstract][Full Text] [Related]
16. PCSK9 inhibition and atherosclerotic cardiovascular disease prevention: does reality match the hype? Hadjiphilippou S; Ray KK Heart; 2017 Nov; 103(21):1670-1679. PubMed ID: 28596304 [TBL] [Abstract][Full Text] [Related]
17. Inclisiran: a small interfering RNA strategy targeting PCSK9 to treat hypercholesterolemia. Banerjee Y; Pantea Stoian A; Cicero AFG; Fogacci F; Nikolic D; Sachinidis A; Rizvi AA; Janez A; Rizzo M Expert Opin Drug Saf; 2022 Jan; 21(1):9-20. PubMed ID: 34596005 [TBL] [Abstract][Full Text] [Related]
18. PCSK9 Biology and Its Role in Atherothrombosis. Barale C; Melchionda E; Morotti A; Russo I Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34070931 [TBL] [Abstract][Full Text] [Related]
19. Inclisiran: A First-in-Class siRNA Therapy for Lowering Low-Density Lipoprotein Cholesterol. Samuel E; Watford M; Egolum UO; Ombengi DN; Ling H; Cates DW Ann Pharmacother; 2023 Mar; 57(3):317-324. PubMed ID: 35775133 [TBL] [Abstract][Full Text] [Related]
20. Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol. Ray KK; Landmesser U; Leiter LA; Kallend D; Dufour R; Karakas M; Hall T; Troquay RP; Turner T; Visseren FL; Wijngaard P; Wright RS; Kastelein JJ N Engl J Med; 2017 Apr; 376(15):1430-1440. PubMed ID: 28306389 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]